Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial

Gouda, Pishoy; Ramasundarahettige, Chinthanie; Anand, Sonia S.; Muhlhoffer, Eva; Berkowitz, Scott D.; Fox, Keith A.A.; Eikelboom, John W.; Welsh, Robert C.

doi:10.1016/j.atherosclerosis.2021.07.003

Cited by 6 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the multifactorial nature of PAD and its chronic development involving diverse metabolic pathways, our hypothesis posits that an integrated model consisting of clinical features and biomarker data can enhance prognostic accuracy compared to the analysis of individual proteins or clinical features alone [ 22 ]. Combining myokine biomarker data with demographic and clinical characteristics associated with PAD outcomes holds potential for developing highly accurate predictive algorithms for adverse limb events linked to PAD [ 23 , 24 , 25 ]. The objective of this study is to identify PAD-specific prognostic biomarkers from a panel of myokines and integrate clinical and myokine biomarker data to build prognostic models for PAD that can guide clinical decision-making.…”

Section: Introductionmentioning

confidence: 99%

The Identification and Evaluation of Interleukin-7 as a Myokine Biomarker for Peripheral Artery Disease Prognosis

Li,

Shaikh,

Zamzam

et al. 2024

JCM

View full text Add to dashboard Cite

Background/Objectives: Myokines have been demonstrated to be associated with cardiovascular diseases; however, they have not been studied as biomarkers for peripheral artery disease (PAD). We identified interleukin-7 (IL-7) as a prognostic biomarker for PAD from a panel of myokines and developed predictive models for 2-year major adverse limb events (MALEs) using clinical features and plasma IL-7 levels. Methods: A prognostic study was conducted with a cohort of 476 patients (312 with PAD and 164 without PAD) that were recruited prospectively. Their plasma concentrations of five circulating myokines were measured at recruitment, and the patients were followed for two years. The outcome of interest was two-year MALEs (composite of major amputation, vascular intervention, or acute limb ischemia). Cox proportional hazards analysis was performed to identify IL-7 as the only myokine that was associated with 2-year MALEs. The data were randomly divided into training (70%) and test sets (30%). A random forest model was trained using clinical characteristics (demographics, comorbidities, and medications) and plasma IL-7 levels with 10-fold cross-validation. The primary model evaluation metric was the F1 score. The prognostic model was used to classify patients into low vs. high risk of developing adverse limb events based on the Youden Index. Freedom from MALEs over 2 years was compared between the risk-stratified groups using Cox proportional hazards analysis. Results: Two-year MALEs occurred in 28 (9%) of patients with PAD. IL-7 was the only myokine that was statistically significantly correlated with two-year MALE (HR 1.56 [95% CI 1.12–1.88], p = 0.007). For the prognosis of 2-year MALEs, our model achieved an F1 score of 0.829 using plasma IL-7 levels in combination with clinical features. Patients classified as high-risk by the predictive model were significantly more likely to develop MALEs over a 2-year period (HR 1.66 [95% CI 1.22–1.98], p = 0.006). Conclusions: From a panel of myokines, IL-7 was identified as a prognostic biomarker for PAD. Using a combination of clinical characteristics and plasma IL-7 levels, we propose an accurate predictive model for 2-year MALEs in patients with PAD. Our model may support PAD risk stratification, guiding clinical decisions on additional vascular evaluation, specialist referrals, and medical/surgical management, thereby improving outcomes.

show abstract